



#X3
DB 1/31/02
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:

Pepinsky, et al.
Serial No: 09/579,680
Filed: May 26, 2000
For: Hydrophobically-Modified Protein Compositions and Methods

JAN 22 2002
Attorney Docket No. TECH CENTER 1600/2900
Art Unit: 1646
Examiner: Not assigned

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this document is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to Office of Initial Patent Examination's Customer Service Center, Assistant Commissioner for Patents, Washington, D.C. 20231, November 2, 2001.


Terrance M. Flynn

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT IN COMPLIANCE WITH 37

CFR §§ 1.97(b) and 1.98(d)

Sir:

Submitted herewith on Form PTO-1449 is a list of publications cited in the parent application (U.S.S.N. 08/854,039, filed May 9, 1997) of the above-referenced application. In accordance with CFR § 1.98 (d), applicants respectfully submit that **no copy** of any patent, publication, or other information listed on the enclosed Form PTO 1449 is needed because the citations were made in the above-mentioned parent application which is relied upon for an earlier filing date under 35 U.S.C. 120.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form 1449.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior

art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Information Disclosure Statement submitted herewith is being filed before the mailing date of a first Office Action on the merits, and as such applicants believe no fees are due at this time. However, should any fees need to be paid in connection with this submission, the Commissioner is hereby authorized to credit any overpayment or charge any deficiencies to/from **Deposit Account No. 18-1945**.

Respectfully submitted,
Ropes & Gray

By: 
David P. Halstead, Ph. D.
Reg. 44,735
Agent for Applicants

Dated: November 2, 2001
Customer No. 28120
Ropes & Gray
Patent Group
One International Place
Boston, MA 02110-2624

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)

JAN 16 2002

Docket Number (Optional)
B1J-P02-067Application Number
09/579,680**RECEIVED**

JAN 22 2002

Applicant
Pepinsky, et al.Filing Date
26-May-2000Group Art Unit
1646**U.S. PATENT DOCUMENTS**

TECH CENTER 1600/2900

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	5,824,315	10/1998	Nag et al	424	195.11	
AB	5,567,317	10/1996	Kauver	210	635	
AC	5,373,548	12/1994	Caras	424	452	
AD	5,399,347	03/21/95	Trentham et al.	424	184	09/25/1992
AD	5,130,297	07/14/92	Sharma et al.	514	8	08/30/1990

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
AE	WO 99/28343	06/10/99	WO				
AF	WO 98/30576	07/16/98	WO			Do Not	
AG	WO 97/40852	11/06/97	WO				
AH	WO 96/29342	09/1996	WO				
AI	WO 96/16668	06/06/96	WO				

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

AJ	Arimili et al., "Antigen-Specific apoptosis in immortalized T cells by soluble MHC class II-peptide complexes", Immunology and Cell Biology 74: 96-104 (1996)
AK	Busconi L. and Denker M.B., " Analysis of the N-terminal Binding domain of G α ". Biochem. J. 328: 23-31 (1997).
AL	Clark et al., "Antigen-specific Deletion Cloned T Cells Using Peptide-Toxin Conjugate Complexed with Purified Class II Major Histocompatibility Complex Antigen", The Journal of Biological Chemistry 269 (1): 94-99 (1994).
AM	Everette, K. et al., "Characterization of Lipoprotein Enva in Chlamydia psittaci 6BC", Journal of Bacteriology, Vol. 176, No. 19, pages 6082-6087.
AN	Karin et al., "Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myelin Basic Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon Y and Tumor Necrosis Factor α Production", J. Exp. Med. 180: 2227-2237 (1994).
AO	Kleuss C. and Gilman G. A., "G α contains an unidentified covalent modification that increases its affinity for adenylyl cyclase" Proc. Natl. Acad. Sci. USA 94 : 6116-6120 (June 1997)
AP	Moll S. T. and Thompson E. T., "semisynthetic Proteins: Model Systems for the Study of the Insertion of Hydrophobic Peptides into Performed Lipid Bilayers", Biochemistry, 33: 15496-15482 (1984).
AQ	Skolnick et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, pages 34-39, 2000.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.